Skip to content
Search

Latest Stories

HayMax balm recognised as 'Best British Allergy Product 2022'

HayMax, maker of the famous organic drug-free allergen barrier balm has been awarded the ‘British Made Award’ for Best British Allergy Product 2022.

The award celebrates businesses that work tirelessly to make their region one of the most diverse and dynamic the UK has to offer.


HayMax MD and creator Max Wiseberg comments: “This award means a great deal to us. We’ve always been proud that our products have been manufactured in the UK. We are passionate about reducing the cost to the environment so being British-made means we keep the miles down and reduce our carbon footprint.”

HayMax balms are manufactured in the UK. It buys local to reduce the cost to the environment, even if it means it costs a bit more. HayMax’s current pots are now made in the UK, which has been great for reducing their carbon footprint. Its tins come from London.

The new pots can be recycled and re-used. The brand has now switched to using sugar cane to make its pots and has also reduced the amount of material used in the pots by just over 54%. And they have switched from the plastic labels to paper labels.

These pots are recyclable with the roadside collection. So now, HayMax is making a positive contribution to climate change, using up CO2 instead of producing it.

HayMax allergen barrier balms are different from most hay fever products, which work by trying to deal with these symptoms. Instead, HayMax seeks to stop the cause of the problem – namely too much pollen in the body – from occurring.

This helps prevent symptoms completely or helps reduce the severity of symptoms by reducing the pollen load. Prevention rather than cure – since there is currently no cure for hay fever.

Independent university studies have shown that HayMax traps significantly more pollen than an uncoated nostril, and traps all types of grass and tree pollen and that HayMax traps over a third of pollen before it enters the body, in addition to dust mite allergens and pet dander. In an independent survey by Allergy UK, the leading national charity providing support, advice and information for those living with allergic disease, 80% of people say HayMax works. And 94% of people find HayMax quick to be effective; 44% said that it worked immediately and a further 35% said that it worked within an hour or two.

HayMax balms are organic, drug-free and non-drowsy which means they’re suitable for children as well as pregnant and breast-feeding mums. They can also be used whilst driving, operating machinery, for exams and sports.

HayMax organic drug-free allergen barrier balms have an rrp of £8.49 per pot and are available from wholesalers to the health store and pharmacy trade, including Hunts Foods, Queenswood, Jumla, CLF, Avvrax, Hampdens, Sundrelle and Sigma, direct on 01525 406600 or www.haymax.biz.

The HayMax range is supported by national PR and advertising campaigns and POS materials, including giant display boxes, CDUs, leaflets, posters and shelf barkers.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less